Middle East & Africa Genotyping Market Forecast to 2028

Report Code : BMIRE00025970 | Region : LAMEA | Industry : Pharmaceuticals | Published Date : 16/Sep/2022
Middle East & Africa Genotyping Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product and Services (Instruments, Reagents and Kits, Bioinformatics, and Genotyping Services), Technology [Microarrays, Capillary Electrophoresis, Sequencing, Polymerase Chain Reaction (PCR), Matrix-Assisted Laser Desorption/Ionization-Time of Flight (Maldi-Tof) Mass Spectrometry, and Others], Application (Pharmacogenomics, Diagnostics and Personalized Medicine, Animal Genetics, Agricultural Biotechnology, and Others), and End User (Pharmaceutical and Biopharmaceutical Companies, Diagnostic and Research Laboratories, Academic Institutes, and Others)

The genotyping market in Middle East & Africa is expected to grow from US$ 1,141.17 million in 2022 to US$ 3,176.29 million by 2028. It is estimated to grow at a CAGR of 18.6% from 2022 to 2028.

Genotyping compares a DNA sequence to another sample or a reference sequence to discover variations in genetic complement. It detects single-nucleotide polymorphisms (SNPs), which are minor differences in genetic sequence within the population. The human genome has about 660 million SNPs, making them the most prevalent kind of genetic variation. They can explain features such as eye color and hereditary disorders such as cystic fibrosis and sickle cell anemia and serve as indicators for developing complicated diseases such as cancer, diabetes, and Alzheimer's.

According to the International Diabetes Federation (IDF) Consortium 2019, type 2 diabetes (T2D) is one of the leading causes of death worldwide, accounting for 4.2 million deaths in 2019. According to the same research, Iran ranks third among 20 countries in the Middle East and North Africa (MENA) in terms of the number of adults with diabetes (5.4 million), estimated that about 9.2 million Iranians may catch the disease by 2030. Type 2 diabetes is a complex metabolic illness caused by genetic and non-genetic (environmental) factors. The heritability of T2D varies between 20% and 80%, indicating that genetic factors play a significant part in the disease's development; the disease's heritable component is polygenic, meaning that multiple genes and their variations contribute to an increased risk of T2D development. The introduction of high-throughput genotyping technologies has greatly advanced our understanding of the genetic components of complex disorders, such as T2D.

Additionally, by comparing polymorphisms in two distinct populations (one healthy and one diseased), genome-wide association studies (GWAS) can uncover links between SNPs and common illness risk. GWAS can begin to untangle the molecular mechanisms underlying disease states by finding probable causative variables risk stratification. Single-celled organisms, such as bacteria, even have SNPs. SNP genotyping can discriminate between microorganism isolates and might even be accustomed to characterizing antibiotic resistance strains. SNP-based strain detection has relevance in each clinical and pharmaceutical analysis and has been used to study the spread of infectious diseases in humans. Over the last decade, next-generation sequencing (NGS) technology has enabled simultaneous testing of multiple disease genes, from targeted gene panels to exome sequencing (ES) and genomic sequencing (GS). GS is quickly becoming a practical first-stage test as costs decrease and performance improves. More and more studies show that GS can detect an unprecedented range of pathogenic abnormalities in a single laboratory. GS has the potential to provide patients with unbiased, rapid, and accurate molecular diagnostics that transcend diverse clinical indications and complex conditions. Therefore, the use in drug development for genetic and rare diseases will be one of the key factors driving the growth of the genotyping markets during the forecast period.

Middle East & Africa Genotyping Market Revenue and Forecast to 2028 (US$ Million)

Middle East & Africa Genotyping Market Segmentation

The Middle East & Africa genotyping market is segmented by products and services, technology, application, end user, and country. Based on products and services, the market is segmented into instruments, reagents and kits, bioinformatics, and genotyping services. The reagents and kits segment is dominating the market in 2022.

Based on technology, the market is segmented into microarrays, capillary electrophoresis, sequencing, matrix-assisted laser desorption/ionization-time of flight (Maldi-ToF) mass spectrometry, polymerase chain reaction (PCR), and others. The PCR segment is dominating the market in 2022.

Based on application, the market is segmented into pharmacogenomics, diagnostics and personalized medicine, animal genetics, agricultural biotechnology, and others. The diagnostics and personalized medicine segment is dominating the market in 2022.

Based on end user, the market is segmented into pharmaceutical and biopharmaceutical companies, diagnostic and research laboratories, academic institutes, and others. The diagnostics and research laboratories segment is dominating the market in 2022.

Based on country, the market is segmented into Saudi Arabia, the UAE, South Africa, and the Rest of the Middle East & Africa. Further, the Rest of the Middle East & Africa is dominating the market in 2022.

A few key players dominating the Middle East & Africa genotyping market are BioTek Instruments, Inc.; F. Hoffmann-La Roche Ltd.; Illumina, Inc.; Integrated DNA Technologies, Inc.; MERCK KGaA; QIAGEN; Thermo Fisher Scientific Inc; and TrimGen Corporation.

The List of Companies - Middle East & Africa Genotyping Market

● BioTek Instruments, Inc.

● F. Hoffmann-La Roche Ltd.

● Illumina, Inc.

● Integrated DNA Technologies, Inc.

● MERCK KGaA

● QIAGEN

● Thermo Fisher Scientific Inc

● TrimGen Corporation

TABLE OF CONTENTS

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 MEA Genotyping Market – By Product and Services

1.3.2 MEA Genotyping Market – By Technology

1.3.3 MEA Genotyping Market – By Application

1.3.4 MEA Genotyping Market – By End User

1.3.5 MEA Genotyping Market – By Country

2. MEA Genotyping Market – Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. MEA Genotyping Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 MEA PEST Analysis

4.3 Experts Opinion

5. MEA Genotyping Market– Key Market Dynamics

5.1 Market Drivers

5.1.1 Use of Genotyping in Drug Development for Genetic and Rare Diseases

5.1.2 Technological Advancements and Rising R&D Investments in Pharmaceutical and Biotechnology

5.2 Market Restraints

5.2.1 High Cost of Equipment and Shortage of skilled Professionals required for Genotyping process

5.3 Market Opportunities

5.3.1 Wide Applications of Genotyping

5.4 Future Trends

5.4.1 Rising focus on Personalized Medicine

5.5 Impact analysis

6. Genotyping Market– MEA Analysis

6.1 MEA Genotyping Market Revenue Forecast and Analysis

7. MEA Genotyping Market– by Product and Services

7.1 Overview

7.2 MEA Genotyping Market, By Product and Services, 2022 & 2028 (%)

7.3 Reagents and Kits

7.3.1 Overview

7.3.2 Reagents and Kits: MEA Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

7.4 Genotyping Services

7.4.1 Overview

7.4.2 Genotyping Services: MEA Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

7.5 Bioinformatics

7.5.1 Overview

7.5.2 Bioinformatics: MEA Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

7.6 Instruments

7.6.1 Overview

7.6.2 Instruments: MEA Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

8. MEA Genotyping Market– by Technology

8.1 Overview

8.2 MEA Genotyping Market Share by Technology - 2022 & 2028 (%)

8.3 Polymerase Chain Reaction (PCR)

8.3.1 Overview

8.3.2 Polymerase Chain Reaction: MEA Genotyping Market Revenue and Forecast to 2028 (US$ Million)

8.4 Capillary Electrophoresis (CE)

8.4.1 Overview

8.4.2 Capillary Electrophoresis: MEA Genotyping Market Revenue and Forecast to 2028 (US$ Million)

8.5 Sequencing

8.5.1 Overview

8.5.2 Sequencing: MEA Genotyping Market Revenue and Forecast to 2028 (US$ Million)

8.6 Microarrays

8.6.1 Overview

8.6.2 Microarrays: MEA Genotyping Market Revenue and Forecast to 2028 (US$ Million)

8.7 Matrix-Assisted Laser Desorption/Ionization-Time of Flight (Maldi-Tof) Mass Spectrometry

8.7.1 Overview

8.7.2 Matrix-Assisted Laser Desorption/Ionization-Time of Flight (Maldi-Tof) Mass Spectrometry: MEA Genotyping Market Revenue and Forecast to 2028 (US$ Million)

8.8 Others

8.8.1 Overview

8.8.2 Others: MEA Genotyping Market Revenue and Forecast to 2028 (US$ Million)

9. MEA Genotyping Market–by Application

9.1 Overview

9.2 MEA Genotyping Market Share by Application - 2022 & 2028 (%)

9.3 Diagnostics and Personalized Medicine

9.3.1 Overview

9.3.2 Diagnostics and Personalized Medicine: MEA Genotyping Market Revenue and Forecast to 2028 (US$ Million)

9.4 Pharmacogenomics

9.4.1 Overview

9.4.2 Pharmacogenomics: MEA Genotyping Market Revenue and Forecast to 2028 (US$ Million)

9.5 Animal Genetics

9.5.1 Overview

9.5.2 Animal Genetics: MEA Genotyping Market Revenue and Forecast to 2028 (US$ Million)

9.6 Agricultural Biotechnology

9.6.1 Overview

9.6.2 Agricultural Biotechnology: MEA Genotyping Market Revenue and Forecast to 2028 (US$ Million)

9.7 Others

9.7.1 Overview

9.7.2 Others: MEA Genotyping Market Revenue and Forecast to 2028 (US$ Million)

10. MEA Genotyping Market– by End User

10.1 Overview

10.2 MEA Genotyping Market Share by End User- 2022 & 2028 (%)

10.3 Diagnostic and Research Laboratories

10.3.1 Overview

10.3.2 Diagnostic and Research Laboratories: MEA Genotyping Market Revenue and Forecast to 2028 (US$ Million)

10.4 Pharmaceutical and Biopharmaceutical Companies

10.4.1 Overview

10.4.2 Pharmaceutical and Biopharmaceutical Companies: MEA Genotyping Market Revenue and Forecast to 2028 (US$ Million)

10.5 Academic Institutes

10.5.1 Overview

10.5.2 Academic Institutes: MEA Genotyping Market Revenue and Forecast to 2028 (US$ Million)

10.6 Others

10.6.1 Overview

10.6.2 Others: MEA Genotyping Market Revenue and Forecast to 2028 (US$ Million)

11. MEA Genotyping Market– Country Analysis

11.1 MEA Genotyping Market Revenue and Forecasts to 2028

11.1.1 Overview

11.1.3 MEA Genotyping Market Revenue and Forecasts to 2028, By Country (%)

11.1.3.1 UAE: Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

11.1.3.1.1 Overview

11.1.3.1.2 UAE: Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

11.1.3.1.3 UAE: Genotyping Market Revenue and Forecasts to 2028, By Product and Services (US$ Million)

11.1.3.1.4 UAE: Genotyping Market, by Technology, 2019–2028 (US$ Million)

11.1.3.1.5 UAE: Genotyping Market Revenue and Forecasts to 2028, By Application (US$ Million)

11.1.3.1.6 UAE: Genotyping Market, by End User – Revenue and Forecast to 2028 (US$ Million)

11.1.3.2 Saudi Arabia: Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

11.1.3.2.1 Overview

11.1.3.2.2 Saudi Arabia: Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

11.1.3.2.3 Saudi Arabia: Genotyping Market Revenue and Forecasts to 2028, By Product and Services (US$ Million)

11.1.3.2.4 Saudi Arabia: Genotyping Market, by Technology, 2019–2028 (US$ Million)

11.1.3.2.5 Saudi Arabia: Genotyping Market Revenue and Forecasts to 2028, By Application (US$ Million)

11.1.3.2.6 Saudi Arabia: Genotyping Market, by End User – Revenue and Forecast to 2028 (US$ Million)

11.1.3.3 South Africa: Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

11.1.3.3.1 Overview

11.1.3.3.2 South Africa Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

11.1.3.3.3 South Africa: Genotyping Market Revenue and Forecasts to 2028, By Product and Services (US$ Million)

11.1.3.3.4 South Africa: Genotyping Market, by Technology, 2019–2028 (US$ Million)

11.1.3.3.5 South Africa: Metabolomics Market Revenue and Forecasts to 2028, By Application (US$ Million)

11.1.3.3.6 South Africa: Genotyping Market, by End User – Revenue and Forecast to 2028 (US$ Million)

11.1.3.4 Rest of MEA: Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

11.1.3.4.1 Overview

11.1.3.4.2 Rest of MEA: Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

11.1.3.4.3 Rest of MEA: Genotyping Market Revenue and Forecasts to 2028, By Product and Services (US$ Million)

11.1.3.4.4 Rest of MEA: Genotyping Market, by Technology, 2019–2028 (US$ Million)

11.1.3.4.5 Rest of MEA: Genotyping Market Revenue and Forecasts to 2028, By Application (US$ Million)

11.1.3.4.6 Rest of MEA: Genotyping Market, by End User – Revenue and Forecast to 2028 (US$ Million)

12. MEA Genotyping Market Industry Landscape

12.1 Overview

12.2 Organic Developments

12.2.1 Overview

12.3 Inorganic Developments

12.3.1 Overview

13. Company Profiles

13.1 F. HOFFMANN-LA ROCHE LTD.

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

13.2 INTEGRATED DNA TECHNOLOGIES, INC. (DANAHER)

13.2.1 Key Facts

13.2.2 Business Description

13.2.3 Products and Services

13.2.4 Financial Overview

13.2.5 SWOT Analysis

13.2.6 Key Developments

13.3 QIAGEN

13.3.1 Key Facts

13.3.2 Business Description

13.3.3 Products and Services

13.3.4 Financial Overview

13.3.5 SWOT Analysis

13.3.6 Key Developments

13.4 MERCK KGaA

13.4.1 Key Facts

13.4.2 Business Description

13.4.3 Products and Services

13.4.4 Financial Overview

13.4.5 SWOT Analysis

13.4.6 Key Developments

13.5 THERMO FISHER SCIENTIFIC INC.

13.5.1 Key Facts

13.5.2 Business Description

13.5.3 Products and Services

13.5.4 Financial Overview

13.5.5 SWOT Analysis

13.5.6 Key Developments

13.6 BioTek Instruments, Inc.

13.6.1 Key Facts

13.6.2 Business Description

13.6.3 Products and Services

13.6.4 Financial Overview

13.6.5 SWOT Analysis

13.6.6 Key Developments

13.7 TRIMGEN CORPORATION

13.7.1 Key Facts

13.7.2 Business Description

13.7.3 Financial Overview

13.7.4 SWOT Analysis

13.7.5 Key Developments

13.8 Illumina, Inc.

13.8.1 Key Facts

13.8.2 Business Description

13.8.3 Products and Services

13.8.4 Financial Overview

13.8.5 SWOT Analysis

13.8.6 Key Developments

14. Appendix

14.1 About The Insight Partners

14.2 Glossary of Terms

LIST OF TABLES.

Table 1.             MEA Genotyping Market –Revenue and Forecast to 2028 (US$ Million)

Table 2.             UAE: Genotyping Market Revenue and Forecasts to 2028, By Product and Services (US$ Million)

Table 3.             UAE: Genotyping Market, by Technology – Revenue and Forecast to 2028 (US$ Million)

Table 4.             UAE: Genotyping Market Revenue and Forecasts to 2028, By Application (US$ Million)

Table 5.             UAE: Genotyping Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 6.             Saudi Arabia: Genotyping Market Revenue and Forecasts to 2028, By Product and Services (US$ Million)

Table 7.             Saudi Arabia: Genotyping Market, by Technology – Revenue and Forecast to 2028 (US$ Million)

Table 8.             Saudi Arabia: Genotyping Market Revenue and Forecasts to 2028, By Application (US$ Million)

Table 9.             Saudi Arabia: Genotyping Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 10.          South Africa Genotyping Market Revenue and Forecasts to 2028, By Product and Services (US$ Million)

Table 11.          South Africa: Genotyping Market, by Technology – Revenue and Forecast to 2028 (US$ Million)

Table 12.          South Africa: Metabolomics Market Revenue and Forecasts to 2028, By Application (US$ Million)

Table 13.          South Africa: Genotyping Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 14.          Rest of MEA: Genotyping Market Revenue and Forecasts to 2028, By Product and Services  (US$ Million)

Table 15.          Rest of MEA: Genotyping Market, by Technology – Revenue and Forecast to 2028 (US$ Million)

Table 16.          Rest of MEA: Genotyping Market Revenue and Forecasts to 2028, By Application (US$ Million)

Table 17.          Rest of MEA: Genotyping Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 18.          Organic Developments Done By Companies

Table 19.          Inorganic Developments Done By Companies

Table 20.          Glossary of Terms

The List of Companies - Middle East & Africa Genotyping Market

● BioTek Instruments, Inc.

● F. Hoffmann-La Roche Ltd.

● Illumina, Inc.

● Integrated DNA Technologies, Inc.

● MERCK KGaA

● QIAGEN

● Thermo Fisher Scientific Inc

● TrimGen Corporation

Reason To Buy

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Middle East & Africa Genotyping Market.

● Highlights key business priorities in order to assist companies to realign their business strategies

● The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa Genotyping Market, thereby allowing players across the value chain to develop effective long-term strategies

● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets

● Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the Genotyping Market, as well as those hindering it

● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution

AVAILABLE CUSTOMIZATION RESEARCH METHODOLOGY REQUEST FOR TOC FREE SAMPLE REPORT
CHOOSE LICENCE TYPE
(Middle East & Africa Genotyping Market Forecast to 2028)
  • Single User Price $3,000$2,400
  • Site Price $4,000$3,200
  • Enterprise Price $5,000$4,000
Buy Now Add to Cart
REQUEST FOR TOC
SPEAK TO ANALYST
FREE SAMPLE
REPORT
INQUIRE BEFORE
BUYING
TOP
Quick Enquiry